A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease.

Trial Profile

A Phase II Study to Evaluate the Efficacy and Safety of 12 Weeks of Treatment With Oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as Compared to Placebo, Followed by a 12 Week Open-label Treatment Period in Patients With Moderately to Severely Active Crohn's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Trichuris suis ova (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TRUST-I
  • Sponsors Fortress Biotech
  • Most Recent Events

    • 30 May 2017 Status changed from active, no longer recruiting to completed.
    • 14 Oct 2013 Top-line results have been reported in a Coronado Biosciences media release.
    • 14 Oct 2013 Primary endpoint of improving response, as assessed by a 100-point decrease in 'Crohn's-Disease-Activity-Index' has not been met according to a Coronado Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top